Arsenic trioxide

Also known as: Arsenic Sesquioxide Arsenic Oxidearsenous Trioxide

Active ingredient description

Arsenic trioxide causes morphological changes and deoxyribonucleic acid (DNA) fragmentation characteristic of apoptosis in NB4 human promyelocytic leukaemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR alpha.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
L01XX27
Arsenic trioxide
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX27

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
TRISENOX Concentrate for solution for infusion
Summary of Product Characteristics (SPC)

Medicines

Arsenic trioxide is the active ingredient of these drugs:

Drug
Countries
ARSENOL

Hong Kong

LEUSENOX

Turkey

PHENASEN

Australia Estonia New Zealand

TRISENOX

Austria Brazil Canada Cyprus Estonia

VARITRINOX

Ecuador

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: As₂O₃
Molecular mass: 197.84 g/mol

External identifiers

CAS Substance: 1327-53-3
DrugBank Drug: DB01169
KEGG Drug: D02106
PubChem Compound: 14888
RxNorm Ingredient: 18330
SNOMED-CT Concept: 72251000
Arsenic trioxide (substance)
UNII Identifier: S7V92P67HO
ARSENIC TRIOXIDE
 
Next: Usage >